Ineligibility for Anticoagulation in Patients with Atrial Fibrillation - 17/01/13
Requests for reprints should be addressed to Jonathan L. Halperin, MD, The Zena and Michael A. Wiener Cardiovascular Institute and The Marie-Josée and Henry R. Kravis Center for Cardiovascular Health, Mount Sinai Medical Center, Fifth Avenue at 100th Street, New York, NY 10029Abstract |
Although anticoagulation therapy markedly reduces the risk of stroke in patients with atrial fibrillation, up to 50% of these patients are deemed ineligible for anticoagulation. In this manuscript we provide a framework to assess the net clinical benefit of anticoagulation in patients with atrial fibrillation with an increased risk of bleeding. We also review recent data related to the novel oral anticoagulants targeting thrombin or factor Xa, and discuss how the introduction of these agents raises the distinction between eligibility for vitamin K antagonist therapy specifically, and eligibility for anticoagulation in general.
Le texte complet de cet article est disponible en PDF.Keywords : Anticoagulation, Atrial fibrillation, Bleeding, Eligibility, Stroke
Plan
| Funding: None. |
|
| Conflicts of Interest: Dr del Conde has no conflicts of interest to report. Dr Halperin holds no employment or shareholder positions and owns no stock or other financial interests in any of the entities pertinent to this manuscript. He serves on no speakers bureaus. He has received consulting fees or research support, during the past 3 years, as follows: Bayer Healthcare, Boehringer Ingelheim, Daiichi-Sankyo Pharma, Janssen Pharmaceuticals, Johnson & Johnson, and Sanofi-Aventis. |
|
| Authorship: Both authors contributed equally in all aspects of this manuscript. |
Vol 126 - N° 2
P. 105-111 - février 2013 Retour au numéro
Article précédent
- Alternate-day Dosing with Statins
- Frank I. Marcus, Adam J. Baumgarten, William L. Fritz, Paul E. Nolan
- White Rings: Arcus Lipoides
- Jorge A. Brenes
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?